Navigation Links
Mexico-US collaboration launched to study major human diseases
Date:1/19/2010

Mexico City, Mexico and Cambridge, MA, USA Tuesday, January 19 Mexican business leader Carlos Slim Hel today announced the launch of a major research project in genomic medicine that will help accelerate progress in public health in Mexico and around the world. The project will be carried out by the Carlos Slim Institute of Health in partnership with the Broad Institute of MIT and Harvard and the National Institute for Genomic Medicine of the Mexican Secretariat of Health. The major goal is to understand the genomic basis of cancer in worldwide populations and of type 2 diabetes in Mexican and Latin American populations.

The project, called Slim Initiative for Genomic Medicine, will last three years and will receive US $65M in support from the Carlos Slim Institute of Health. It will leverage the Broad Institute's expertise and capabilities in the most advanced technologies in genomic sequencing.

The project also involves the training of Mexican experts under the leadership of the National Institute of Genomic Medicine of the Mexican Secretariat of Health, the leading institution in genomic research in Latin America.

The findings of this research will help accelerate both the prevention of disease as well as the development of improved therapies in Mexico and beyond.

Referring to the importance of the project, Carlos Slim said, "I am convinced that only through genomics will we be able to face the costly burden of illnesses that strain the budgets of even the richest countries."

"Carlos Slim is making a visionary commitment to public health in the Americas in two ways," said Dr. Eric S. Lander, director and president of the Broad Institute of MIT and Harvard. "First, in recognizing that progress in public health must be built on a foundation of scientific understanding of the genetic basis of disease. Second, in recognizing that deepening the scientific ties between the US and Mexico can have great benefits for both countries. We look forward to making common cause with our colleagues in Mexico."

The research project will make use of new technologies for decoding or "sequencing" DNA, which have made it possible for researchers to study DNA more rapidly and at a lower cost than ever before. In cancer, the scientists will create catalogs of the genetic abnormalities (called "mutations") that occur across different cancer types. Such knowledge aims to reveal key genetic weaknesses that can be exploited by new cancer therapies and to identify which patients are most likely to respond to specific cancer drugs.

In type 2 diabetes, the researchers will also assemble systematic descriptions of the genetic factors underlying the disease, with a special focus on Latin American populations. Diabetes is among the most common inherited diseases in Latin America, yet a deep knowledge of the genetic risk factors in the region's populations is lacking. A profound understanding of these factors is needed in order to foster prevention, treatment, and control.

During the three years of the project, major findings will be publicly announced. In order to guarantee that the project benefits science and the population in general, the main recipient of its findings will be the National Institute for Genomic Medicine.

To supervise the scientific progress of the project a Scientific Advisory Board has been established. It is composed of renowned scientists from around the world with vast experience in the fields of cancer, diabetes, and genomic science.


'/>"/>

Contact: Nicole Davis
ndavis@broadinstitute.org
617-714-7152
Broad Institute of MIT and Harvard
Source:Eurekalert

Related biology news :

1. BASF and Harvard University announce extensive research collaboration
2. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
3. Conference on healthspan offers new opportunities for interdisciplinary collaboration
4. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
5. Major international collaboration offers new clues to genetics of type 2 diabetes
6. Major collaboration uncovers surprising new genetic clues to diabetes
7. Iowa State-ConocoPhillips collaboration advances 26 research projects in first year
8. US and UK research centers launch major collaboration on atmospheric research, technology
9. Gladstone scientists create Wikipathways to foster research collaboration
10. OHSU commercial collaborations have surged
11. Collaboration between researchers yields more comprehensive portrait of brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: